
Maria G Valdovinos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/528601/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Treating challenging behavior in twins diagnosed with Down syndrome: Measuring treatment integrity and collecting social validity Behavior Analysis (Washington, D C), 2023, 23, 60-68.	0.5	0
2	Descriptive Longitudinal Analysis of Stereotypy and Corresponding Changes in Psychotropic Medication. Developmental Neurorehabilitation, 2022, 25, 298-308.	1.1	0
3	Effects of clonidine on progressive ratio schedule performance in Fmr1 knockout mice. Psychopharmacology, 2021, 238, 1133-1140.	3.1	3
4	Changes in Stereotypical Behavior Following Chlorpromazine Termination: Polypharmacy Effects on Response Class Membership. Advances in Neurodevelopmental Disorders, 2020, 4, 247-252.	1.1	0
5	Psychotropic Medication in Intellectual and Developmental Disabilities: Patterns of Use and Recommendations for Monitoring Effects. Current Developmental Disorders Reports, 2019, 6, 195-201.	2.1	7
6	Characterizing Mood States in Individuals Diagnosed with Bipolar Disorder and Intellectual Disability. Journal of Mental Health Research in Intellectual Disabilities, 2019, 12, 26-44.	2.0	3
7	Evaluating the relationship between the rate and temporal distribution of self-injurious behavior Behavior Analysis (Washington, D C), 2019, 19, 72-80.	0.5	0
8	Adverse Side Effects of Psychotropic Medication and Challenging Behavior: Pilot Work Assessing Impact. Journal of Developmental and Physical Disabilities, 2017, 29, 969-982.	1.6	11
9	A review of research on direct-care staff data collection regarding the severity and function of challenging behavior in individuals with intellectual and developmental disabilities. Journal of Intellectual Disabilities, 2016, 20, 296-306.	1.4	6
10	Assessing the impact of psychotropic medication changes on challenging behavior of individuals with intellectual disabilities. International Journal of Developmental Disabilities, 2016, 62, 200-211.	2.0	20
11	Health Conditions, Learning, and Behavior. Evidence-based Practices in Behavioral Health, 2016, , 1-19.	0.3	0
12	Functional Analysis of Phenotypic Behaviors of a 5-Year-Old Male with Novel 4q21 Microdeletion. Journal of Pediatric Neuropsychology, 2015, 1, 36-41.	0.6	1
13	Effects of clonidine and methylphenidate on motor activity in Fmr1 knockout mice. Neuroscience Letters, 2015, 585, 109-113.	2.1	14
14	Should clinical trial research of psychotropic medication in autism control for gastrointestinal symptoms?. Journal of Clinical Pharmacology, 2014, 54, 1093-1096.	2.0	0
15	Brief Report: Altered Social Behavior in Isolation-RearedÂFmr1ÂKnockout Mice. Journal of Autism and Developmental Disorders, 2013, 43, 1452-1458.	2.7	15
16	The Use of Reinforcer Assessments in Evaluating Psychotropic Medication Effects. Journal of Developmental and Physical Disabilities, 2012, 24, 515-528.	1.6	9
17	Results of a Nation-Wide Survey Evaluating Psychotropic Medication Use in Fragile X Syndrome. Journal of Developmental and Physical Disabilities, 2009, 21, 23-37.	1.6	20
18	Social validity of behavioral practices in the treatment of autism—A review of the Super Nanny. Research in Autism Spectrum Disorders, 2009, 3, 173-178.	1.5	2

#	Article	IF	CITATIONS
19	Using Analogue Functional Analysis to Measure Variations in Problem Behavior Rate and Function After Psychotropic Medication Changes: A Clinical Demonstration. Journal of Mental Health Research in Intellectual Disabilities, 2009, 2, 279-293.	2.0	23
20	Brief review of current research in FXS: Implications for treatment with psychotropic medication. Research in Developmental Disabilities, 2007, 28, 539-545.	2.2	7
21	Relevance of Donepezil in Enhancing Learning and Memory in Special Populations: A Review of the Literature. Journal of Autism and Developmental Disorders, 2007, 37, 1883-1901.	2.7	47
22	Blood glucose levels and problem behavior. Research in Developmental Disabilities, 2006, 27, 227-231.	2.2	13
23	Medical and Behavioral Symptoms as Potential Medication Side Effects in Adults With Developmental Disabilities. American Journal on Intellectual and Developmental Disabilites, 2005, 110, 164.	2.4	38
24	Effects of Risperidone on Destructive Behavior of Persons With Developmental Disabilities: III. Functional Analysis. American Journal on Intellectual and Developmental Disabilites, 2004, 109, 310.	2.4	62
25	A behavior-analytic conceptualization of the side effects of psychotropic medication. The Behavior Analyst, 2004, 27, 231-238.	2.5	26
26	Use of functional analysis methodology in the evaluation of medication effects. Journal of Autism and Developmental Disorders, 2003, 33, 271-279.	2.7	48
27	Title is missing!. Journal of Developmental and Physical Disabilities, 2003, 15, 299-334.	1.6	4
28	Prevalence and Correlates of Psychotropic Medication Use among Adults with Developmental Disabilities: 1970–2000. International Review of Research in Mental Retardation, 2003, 26, 175-220.	0.7	16
29	Multimodal evaluation of risperidone for destructive behavior: Functional analysis, direct observations, rating scales, and psychiatric impressions Experimental and Clinical Psychopharmacology, 2002, 10, 268-275.	1.8	23